Carisma Therapeutics Receives FDA Clearance of Investigational New Drug Application for CT-0525, a Novel CAR-M Cell Therapy
Having received a Study May Proceed notification from the FDA, Carisma plans to initiate a Phase 1 study in the months to come and to treat the first patient in the first half of 2024.
Technical.ly published an article about the future of the growth of the life sciences in Philadelphia, highlighting Penn’s role in the development of the city as a strong tech hub.
Technical.ly State of the Philadelphia Tech Economy Report Highlights Innovation Accomplishments at Penn
According to the report, Penn ranked within the top five largest research & development expenditures of US universities in 2021.
ViTToria Biotherapeutics Raises Over $15 Million in Private Financing Round to Support the Development of Novel CAR-T Cell Therapy Lead Candidate, VIPER-101
ViTToria is focused on developing novel CAR-T cell therapies that transcend the limitations of current cell therapies.
Penn spinout Vivodyne closed a $38 million seed funding round led by Khosla Ventures.
The company plans to initiate a Phase 1/2 clinical trial of CABA-201 in two cohorts of patients with generalized myasthenia gravis (gMG).
Heirloom uses a process called direct air capture to remove greenhouse gases from the atmosphere.
Vetigenics announced that the first canine patient has received his first dose of Vetigenics' fully canine anti-CTLA4 monoclonal antibody (VGS-001) for oral melanoma.
Cabaletta Bio Receives FDA Clearance of CABA-201 Investigational New Drug Application for Treatment of Generalized Myasthenia Gravis
Cabaletta Bio received FDA clearance for their fourth Investigational New Drug application of CABA-201, their CAR T cell investigational therapy, to treat patients with generalized myasthenia gravis.
Co-founded by Saar Gill, MD, PhD, Interius is developing a new platform for cell-specific gene delivery in patients.